While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

Patients taking Ozempic ... 0.25 mg only approved for initiation and not maintenance),” a Novo Nordisk spokesperson said in ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

So what is semaglutide and who uses it in India? Semaglutide belongs to the class of drugs called Glucagon-like peptide-1 ...

Losing weight on GLP-1 drugs like Ozempic isn't guaranteed. Experts reveal how to tell if yours isn't working and the next steps you should take to reach your weight loss goals.

On Friday, Novo Nordisk A/S (NYSE:NVO) released headline results from part 1 of the ongoing ESSENCE Phase 3 trial, a 240-week ...

Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Clinical trial results have revealed that semaglutide treatment significantly reduced hospital admissions in overweight and ...

In the ESSENCE trial, semaglutide improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis ...

Also Read: Ozempic Can Potentially ... data from the SOUL Phase 3 cardiovascular outcomes trial that evaluated subcutaneous once-weekly (injectable) semaglutide 2.4 mg. The trial achieved its ...